NeoImmuneTech, Inc. (KOSDAQ:950220)

NeoImmuneTech Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	208.5	170.38	-	-	-	-
Gross Profit	6,055	170.38	-	-	-	-
Selling, General & Admin	36,533	36,534	52,369	55,326	50,090	8,134
Research & Development	-0.19	-	-	-	-	22,704
Operating Expenses	41,142	41,143	55,847	58,182	51,906	31,270
Operating Income	-35,087	-40,972	-55,847	-58,182	-51,906	-31,270
Interest Expense	-2,502	-726.09	-225.28	-261.39	-219.15	-185.79
Interest & Investment Income	2,693	1,788	2,877	1,154	390.88	952.88
Currency Exchange Gain (Loss)	-1,335	-1,335	-128.89	-3,005	-589.4	-79.28
Other Non Operating Income (Expenses)	2,236	1,187	23.06	18.52	15.46	0.35
EBT Excluding Unusual Items	-33,995	-40,059	-53,301	-60,276	-52,308	-30,582
Gain (Loss) on Sale of Assets	-321.85	-321.85	-1.91	-13.03	-104.72	152.62
Asset Writedown	-488.92	-488.92	-	-	-	-
Pretax Income	-34,806	-40,870	-53,303	-60,289	-52,413	-30,429
Income Tax Expense	-106.82	12.83	101.3	116.41	69.47	27.29
Net Income	-34,699	-40,883	-53,405	-60,406	-52,482	-30,456
Net Income to Common	-34,699	-40,883	-53,405	-60,406	-52,482	-30,456
Shares Outstanding (Basic)	99	99	99	99	95	83
Shares Outstanding (Diluted)	99	99	99	99	95	83
Shares Change (YoY)	-	0.02%	0.08%	3.68%	15.27%	1.50%
EPS (Basic)	-350.96	-413.51	-540.26	-611.60	-550.94	-368.52
EPS (Diluted)	-350.96	-413.60	-540.40	-611.60	-550.94	-368.52
Free Cash Flow	-36,613	-43,768	-50,552	-44,881	-36,596	-29,993
Free Cash Flow Per Share	-370.32	-442.70	-511.40	-454.42	-384.18	-362.92
Gross Margin	-	100.00%	-	-	-	-
Operating Margin	-16828.46%	-24047.07%	-	-	-	-
Profit Margin	-16642.51%	-23994.58%	-	-	-	-
Free Cash Flow Margin	-17560.60%	-25688.01%	-	-	-	-
EBITDA	-31,128	-37,014	-52,637	-55,380	-50,033	-30,282
D&A For EBITDA	3,958	3,959	3,210	2,802	1,873	987.98
EBIT	-35,087	-40,972	-55,847	-58,182	-51,906	-31,270

Source: S&P Global Market Intelligence. Standard template. Financial Sources.